Steven J. Romano - 02 Jan 2026 Form 4 Insider Report for Silence Therapeutics plc (SLN)

Role
EVP and Chief R&D Officer
Signature
/s/ Rhonda Hellums, Attorney-in-Fact
Issuer symbol
SLN
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 16:15:13 UTC
Previous filing
22 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Romano Steven J. EVP and Chief R&D Officer C/O SILENCE THERAPEUTICS PLC, 12 HAMMERSMITH GROVE, LONDON, UNITED KINGDOM /s/ Rhonda Hellums, Attorney-in-Fact 06 Jan 2026 0001639860

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLN Employee Share Option (Right to Buy) Award $0 +300,000 $0.000000 300,000 02 Jan 2026 Ordinary Shares 300,000 $2.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.